HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio's pipeline.

Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to accelerate clinical translation, enhance CMC execution efficiency, and support scalable global development and manufacturing of HanchorBio's innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.

This partnership reflects HanchorBio's strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics' proven capabilities in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs.

WuXi Biologics brings extensive experience in complex modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, WuXi Biologics' integrated platform supports 945 projects, approximately 60% of which involve bi- and multi-specific antibodies, ADCs, and fusion proteins, underscoring its strong track record in accelerating the development and manufacturing of advanced therapeutic modalities. Its proprietary technology platforms, such as WuXia™ TrueSite targeted integration (TI)-based CHO cell line platform and WuXiHigh^TM high-throughput formulation development platform, are designed to enhance speed, quality, and scalability.

For HanchorBio, the collaboration supports continued expansion of its proprietary FBDB™ technology platform, which enables the rational design of multi-functional fusion proteins intended to modulate both innate and adaptive immunity. The partnership represents a significant step in aligning discovery innovation with industrial-scale and globally compliant execution as HanchorBio advances its oncology and autoimmune pipelines toward global clinical development.

Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio, commented: "This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics' proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline."

Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said: " We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics' comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio's innovative bi-/multi fusion proteins and help bring transformative therapies to patients worldwide.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio's proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies. 

For more information, please visit: https://www.HanchorBio.com

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

Galloping into the New Year of the Horse with the community as it looks ahead to its 135^th anniversary in Hong Kong

HONG KONG, Jan. 26, 2026 /PRNewswire/ -- Sun Life is proud to be the title sponsor of "Sun Life 'The Big Bounce' World Tour - Hong Kong", which will take place from 6 to 22 February 2026 at the Great Lawn of the Art Park in the West Kowloon Cultural District.

Timed to coincide with the Chinese New Year and spanning 17 days, this bouncing extravaganza brings the public an energetic, joyful and festive experience that invites the community to leap into the New Year with boundless fun and create unforgettable memories together. As part of Sun Life's celebrations marking its approaching 135^th anniversary, the event underscores the company's long-standing commitment to helping people live healthier, more fulfilling lives.

Adley Low, Chief Client and Marketing Officer at Sun Life Hong Kong Limited, said: "Sun Life has been rooted in Hong Kong for well over a century, supporting generations of Hong Kong people through each chapter of their lives and witnessing the city's transformation and progress across different eras. We're thrilled to jumpstart our 135^th anniversary celebrations as the title sponsor of "Sun Life 'The Big Bounce' World Tour – Hong Kong". At Sun Life, we value our deep connection with the community and are firmly committed to promoting healthier, more active lifestyles for our Clients. Through this exciting event, together with Hong Kongers, we hope to leap into the Year of the Horse, inspiring everyone to stay active and share laughter."

"Sun Life 'The Big Bounce' World Tour – Hong Kong" highlights:

• Event site covers more than 100,000 square feet
• Features four mega inflatable play zones:
  • The world's biggest bounce house spanning 16,000 square feet, certified by Guinness World Record
  • The Giant, Hong Kong's longest inflatable obstacle course stretching over 150 meters
  • Sport Slam, an arena for sports enthusiasts
  • airSPACE Pink Alien, an outer‑space themed inflatable zone

• The event offers dedicated daytime family sessions and Cantopop-themed nighttime bounce parties, ensuring everyone – from children to adults – can jump in and let loose.

Tickets are available now through designated online platforms until 22 February 2026. For ticket prices and the latest details, visit the official website.

"Sun Life 'The Big Bounce' World Tour – Hong Kong" Event Details

Date	6-22 February, 2026
Venue	Great Lawn, Art Park, West Kowloon Cultural District
Opening Hours	9:15am - 11:00pm (with different time slots)
Event Highlights	•     100,000 square feet of inflatable fun party •     Features four mega inflatable play zones: o    The world's biggest bounce house spanning 16,000 square feet, certified by Guinness World Record o    The Giant, Hong Kong's longest inflatable obstacle course stretching over 150 meters o    Sport Slam, an arena for sports enthusiasts o    airSPACE Pink Alien, an outer‑space themed inflatable zone •     "After Dark Party" features a Cantopop theme •     Special anime cosplay days with INCUBASE Arena •     New "After Dark Bigger Kids" sessions for families
Standard Ticket Prices*	Junior Sessions / Bigger Kids Sessions / After Dark Bigger Kids Sessions: HK$179 After Dark Party (ages 18 or above): HK$199 (Regular price) * Each ticket is a 90-minute pass, providing access to the World's Biggest Bounce House during a designated 40-minute time slot, as well as unlimited access to all other attractions. For more details, please refer to the official website.

Date

6-22 February, 2026

Venue

Great Lawn, Art Park, West Kowloon Cultural District

Opening Hours

9:15am - 11:00pm (with different time slots)

Event Highlights

•     100,000 square feet of inflatable fun party

•     Features four mega inflatable play zones:

o    The world's biggest bounce house spanning 16,000 square feet, certified by Guinness World Record

o    The Giant, Hong Kong's longest inflatable obstacle course stretching over 150 meters

o    Sport Slam, an arena for sports enthusiasts

o    airSPACE Pink Alien, an outer‑space themed inflatable zone

•     "After Dark Party" features a Cantopop theme

•     Special anime cosplay days with INCUBASE Arena

•     New "After Dark Bigger Kids" sessions for families

Standard Ticket Prices*

Junior Sessions / Bigger Kids Sessions / After Dark Bigger Kids Sessions: HK$179

After Dark Party (ages 18 or above): HK$199 (Regular price)

* Each ticket is a 90-minute pass, providing access to the World's Biggest Bounce House during a designated 40-minute time slot, as well as unlimited access to all other attractions. For more details, please refer to the official website.

 

About Sun Life

Sun Life is a leading international financial services organisation providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including: Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, Mainland China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of September 30, 2025, Sun Life had total assets under management of $1.62 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life Financial Inc. is the holding company of Sun Life Assurance Company of Canada. Sun Life Hong Kong Limited (incorporated in Bermuda with limited liability) is a wholly-owned subsidiary of Sun Life Assurance Company of Canada and operates in Hong Kong.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Sun Life announced as title sponsor of "Sun Life 'The Big Bounce' World Tour - Hong Kong"